Role of (18)F-DOPA PET/CT and (131)I-MIBG planar scintigraphy in evaluating patients with pheochromocytoma.

Autor:	Bandopadhyaya GP; Department of Nuclear Medicine & PET, All India Institute of Medical Sciences, New Delhi, India. guru47@gmail.com., Kumar A, Kumari J
Jazyk:	angličtina
Zdroj:	Hellenic journal of nuclear medicine [Hell J Nucl Med] 2015 Sep-Dec; Vol. 18 Suppl 1, pp. 141.
Abstrakt:	Objective: The aim of this retrospective study was to evaluate role of (18)F-DOPA PET/CT and (131)I-MIBG planar scintigraphy in patients with pheochromocytoma. Methods: The patients with diagnosis of pheochromocytoma based on radiological and biochemical markers were retrospectively selected for the study. These patients had undergone both (131)I-MIBG scintigraphy and (18)F-DOPA PET/CT. The imaging findings were compared to patient histopathology reports, biochemical markers and clinical follow up whenever available to establish the diagnosis. Results: (131)I-MIBG showed a sensitivity of 68% and specificity of 100%. (18)F-DOPA PET/CT showed a sensitivity of 82% and specificity of 100%. (18)F-DOPA was better at localizing and finding more no of lesions as compared to (131)I-MIBG scintigraphy. (18)F-DOPA also is a better study in evaluation of paragangliomas. Conclusions: (18)F-DOPA PET/CT seems to be a better modality in comparison to (131)I-MIBG scintigraphy in the evaluation of pheochromocytoma/paraganglioma. At this point both these tracers seem to have mutually additive role in these patients and essential investigations with diagnosis and follow-up of this disease.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu